Immunomedics, Inc. Named Edison Patent Award Winner in Biotechnology by Research & Development Council of New Jersey

MORRIS PLAINS, N.J., Nov. 9, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the Company was honored by the Research & Development Council of New Jersey with their coveted Edison Patent Award, in recognition of the Company's significant achievements in the biotechnology category for its DOCK-AND-LOCK™ (DNL™) protein engineering platform technology.